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Bone formation and hematopoiesis are anatomically juxtaposed and share common regulatory mechanisms. Bone marrow mes-
enchymal stromal/stem cells (MSC) contain a compartment that provides progeny with bone forming osteoblasts and fat laden
adipocytes as well as ﬁbroblasts, chondrocytes, and muscle cells. In addition, marrow MSC provide an environment for sup-
port of hematopoiesis, including the development of bone resorbing osteoclasts. The PPARγ2 nuclear receptor is an adipocyte-
speciﬁc transcription factor that controls marrow MSC lineage allocation toward adipocytes and osteoblasts. Increased expression
of PPARγ2 with aging correlates with changes in the MSC status in respect to both their intrinsic diﬀerentiation potential and pro-
duction of signaling molecules that contribute to the formation of a speciﬁc marrow micro-environment. Here, we investigated
the eﬀe c to fP P A R γ2 on MSC molecular signature in respect to the expression of gene markers associated exclusively with stem
cell phenotype, as well as genes involved in the formation of a stem cell supporting marrow environment. We found that PPARγ2
is a powerful modulator of stem cell-related gene expression. In general, PPARγ2a ﬀects the expression of genes speciﬁc for the
maintenance of stem cell phenotype, including LIF, LIF receptor, Kit ligand, SDF-1, Rex-1/Zfp42, and Oct-4. Moreover, the antidi-
abetic PPARγ agonist TZD rosiglitazone speciﬁcally aﬀects the expression of “stemness” genes, including ABCG2, Egfr, and CD44.
Our data indicate that aging and anti-diabetic TZD therapy may aﬀect mesenchymal stem cell phenotype through modulation of
PPARγ2 activity. These observations may have important therapeutic consequences and indicate a need for more detailed studies
of PPARγ2 role in stem cell biology.
Copyright © 2007 K. R. Shockley et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
PPARγ, an essential regulator of lipid, glucose, and insulin
metabolism [1] ,i se x p r e s s e di nb o n em a r r o wm e s e n c h y m a l
stem cells (MSC). PPARγ is expressed in mice and humans
in two isoforms, PPARγ1a n dP P A R γ2, which originate from
up to seven diﬀerent transcripts due to alternative promoter
usage and alternative splicing [2–5]. PPARγ2d i ﬀers from
PPARγ1 by 30 additional amino acids on its N-terminus,
which constitute AF-1 domain of ligand-independent gene-
activating function [6]. While PPARγ1 is expressed in a vari-
ety of cell types, including osteoblasts, PPARγ2 is expressed
in cells of adipocyte lineage and serves as an essential regula-
tor of adipocyte diﬀerentiation and function [7, 8].
Osteoblasts and adipocytes are derived from a marrow
mesenchymal cell compartment which also serves as a source
of progenitors for marrow ﬁbroblasts and cartilage cells and
functionsashematopoiesis-supporting stroma[9,10].Com-
mitment of marrow MSC toward adipocyte and osteoblast
lineage occurs by a stochastic mechanism, in which lineage-
speciﬁc transcription factors (such as Runx2 for osteoblasts
and PPARγ2 for adipocytes) representing intrinsic deter-
minants of this process are activated [8, 11]. Embryonic
stem cells with a null mutation in PPARγ spontaneously dif-
ferentiate to osteoblasts and are unable to diﬀerentiate to
adipocytes [12]. In marrow MSC, PPARγ2a c t sa sad o m i -
nant negative regulator of osteoblast diﬀerentiation [8, 13].
Using a model of marrow MSC diﬀerentiation (U-33/γ2
cells),wehavepreviouslydemonstratedthatactivationofthe
PPARγ2 isoform by the highly speciﬁc agonist and antidia-
betic thiazolidinedione (TZD), rosiglitazone, converted cells
of osteoblast lineage to terminally diﬀerentiated adipocytes2 PPAR Research
Table 1
(a) Genes expressed diﬀerently in P versus V.
Gene symbol Probe IDa FCb Gene description Biological processc
Cd3g 1419178 at 1.5 CD3 antigen, gamma
polypeptide
Immune and hematopoietic system, cell
surface receptor linked signal
transduction
Cd3e 1445748 at 1.5 CD3 antigen, epsilon
polypeptide
Cell surface receptor linked signal
transduction, positive regulation of T
cell proliferation and T cell receptor
signaling pathway
Cd4 1419696 at 1.5 CD4 antigen
Immune response, cell adhesion, cell
surface receptor linked signal
transduction, positive regulation of T
cell activation
Cd7 1419711 at 1.5 CD7 antigen Immune response, myeloid cells
antigen
Cd8a 1451673 at 1.7 CD8 antigen, alpha chain
Immune response, cell surface receptor
linked signal transduction, cellular
defense response, cytotoxic T cell
diﬀerentiation
Cd19 1450570 a at 1.9 CD19 antigen Lymphocyte progenitors
Cd24a 1416034 at 9.8 CD24a antigen
Cell surface antigen expressed in T and
B lymphocytes, macrophages, dendritic
endothelial, and epithelial cells
Cd33 1450513 at 1.5 CD33 antigen Myeloid cells antigen, cell adhesion
Cd37 1419206 at 1.7 CD37 antigen B and T cell antigen
Cd96 1419226 at 1.5 CD96 antigen T-cell activation, cell adhesion
Cd207 1425243 at 1.5 CD 207 antigen Speciﬁc for Langerhans cell precursors
Cd209b 1426157 a at 1.7 CD209b antigen
Dendritic cell-speciﬁc, positive
regulation of tumor necrosis
factor-alpha biosynthesis, positive
regulation of phagocytosis
Cd209c 1421562 at 1.9 CD209c antigen Dendritic cell speciﬁc
Cxcl9 1418652 at 1.6 Chemokine (C-X-C motif)
ligand 9
Inﬂammatory response, immune
response
Cxcl13 1448859 at 2.0 Chemokine (C-X-C motif)
ligand 13
Chemotaxis, inﬂammatory response,
immune response, lymph node
development
Cxcl16 1418718 at 1.7 Chemokine (C-X-C motif)
ligand 16
Chemotaxis, keratinocytes, released
into the wound after injury
Fgf4 1450282 at 1.8 Fibroblast growth factor 4
Trophoblast proliferation and
diﬀerentiation, regulation of
progression through cell cycle, stem cell
maintenance, embryonic limb and
hindlimb morphogenesis,
odontogenesis, negative regulation of
apoptosis
Gata4 1441364 at 1.6 GATA binding protein 4
Embryonic development, regulation of
transcription, heart development,
embryonic gut morphogenesis
Gjb1 1448766 at 1.6 Gap junction membrane
channel protein beta 1 Cell communication, cell-cell signaling
Kit/CD117 1452514 a at 1.6 Kit oncogene
Germ cell development,
transmembrane receptor protein
tyrosine kinase signaling pathway, cell
proliferation, cytokine and chemokine
mediated signaling pathway,
hematopoiesis, cell diﬀerentiationK. R. Shockley et al. 3
(a) Continued.
Gene symbol Probe IDa FCb Gene description Biological processc
Kdr 1449379 at 1.6 Kinase insert domain
protein receptor
Angiogenesis, vasculogenesis,
transmembrane receptor protein
tyrosine kinase signaling
pathway, development, cell
migration, hemopoiesis, cell
diﬀerentiation, cell fate
commitment, endothelial cell
diﬀerentiation
Nkx2-5 1449566 at 1.9 NK2 transcription factor
related, locus 5
Regulation of transcription,
embryonic heart tube
development
Psca 1451258 at 1.5 Prostate stem cell antigen
Pou3f2 1450831 at 1.7 POU domain, class 3,
transcription factor 2
Positive regulation of cell
proliferation, regulation of
transcription
Pou5f1/Oct-4 1417945 at 1.5 POU domain, class 5,
transcription factor 1
Germ-line stem cell
maintenance, expressed in
mouse totipotent embryonic
stem and germ cells, regulation
of transcription
Sox10 1451689 a at 2.3 SRY-box containing gene
10
Regulation of transcription, cell
diﬀerentiation and maturation
Thy1/CD90 1423135 at 1.5 Thymus cell antigen 1,
theta MSC speciﬁc marker
Utf1 1416899 at 1.5
Undiﬀerentiated
embryonic cell
transcription factor 1
Regulation of transcription
Col4a3bp 1420384 at −1.6 Procollagen, type IV, alpha
3 binding protein
Goodpasture antigen binding
protein
Egr2/Krox20 1427683 at −3.9 Early growth response 2
Schwann cell diﬀerentiation,
myelination, rhythmic behavior,
regulates osteocalcin expression
Falz 1427310 at −3.2 Fetal Alzheimer antigen Negative regulation of
transcription
H2-K1 1426324 at −4.2 Histocompatibility 2, K1, K
region
Immune response, antigen
presentation, endogenous
antigen via MHC class I
Lif 1421207 at −8.7
Leukemia inhibitory factor
(transient downregulation
during cell growth)
Embryonic stem cell
maintenance, immune response,
tyrosine phosphorylation of
Stat3 protein, muscle
morphogenesis, neuron
development
Lifr 1425107 a at −5.8 Leukemia inhibitory factor
receptor
Positive regulation of cell
proliferation
TNFRSF11b/OPG 1449033 aat −34.6
T u m o rn e c r o s i sf a c t o r
receptor superfamily,
member 11b
(osteoprotegerin)
Apoptosis, signal transduction,
negative regulation of
osteoclastogenesis
Zfp42/Rex-1 1451244 a at −1.9 Zinc ﬁnger protein 42
T h ep u t a t i v eh u m a ns t e mc e l l
marker, Rex-1 (Zfp42): structural
classiﬁcation and expression in
normal human epithelial and
carcinoma cell cultures
a Aﬀymetrix probe ID
b fold change
c gene ontology [28]4 PPAR Research
Table 1
(b) Genes expressed diﬀerently in PR versus P.
Gene symbol Probe IDa FCb Gene Description Biological Processc
Abcg2 1422906 at −3.1 ATP-binding cassette,
subfamily G, member 2 Stem cell marker, drug resistance
Cd9 1416066 at −3.2 CD9 antigen Stromal cell and adipose stem cell
surface marker, tetraspan protein
Cd47 1419554 at −2.4 CD47 antigen (Rh-related
antigen,
Hematopoietic cells, membrane
glycoprotein, the same as
integrin-associated protein (IAP)
and ovarian tumor marker OA3
Cd81 1416330 at −1.6 CD 81 antigen Cell adhesion, fertilization
Egfr 1424932 at −1.8 Epidermal growth factor
receptor
Active in early events of stem cells
recruitment and diﬀerentiation
Gja7 1449094 at −3.8 Gap junction membrane
channel protein alpha 7
Cell communication, synaptic
transmission, heart development,
v i s u a lp e r c e p t i o n ,c e l ld e v e l o p m e n t ,
cardiac muscle development
Il6st 1437303 at −2.9 Interleukin 6 signal
transducer
Signal transduction, positive
regulation of cell proliferation,
regulation of Notch signaling
pathway
Lims1 1418231 at −2.5 LIM and senescent cell
antigen-like domains 1
Cell-matrix adhesion,
establishment and/or maintenance
of cell polarity, cell-cell adhesion,
embryonic development
Cd36 1423166 at 178.8 CD36 antigen Fatty acid transporter associated
with adipogenesis
Cd200 (Ox2) 1448788 at 2.4 Cd200 antigen
Cell surface antigen of thymocytes,
B cells, T cells, neurons, kidney
glomeruli, tonsil follicles, the
syncytiotrophoblast and endothelial
cells
Cd5 1418353 at 1.6 CD5 antigen B lymphocytes antigen
Cd63 1455777x at 1.9 Cd63 antigen Melanoma antigen
Vegfa 1451959 a at 1.5 Vascular endothelial
growth factor A
Regulation of progression through
cell cycle, angiogenesis,
development, cell proliferation, cell
diﬀerentiation
Vegfb 1451803 a at 2.6 Vascular endothelial
growth factor A
Regulation of progression through
cell cycle, angiogenesis,
development, cell proliferation, cell
diﬀerentiation
a Aﬀymetrix probe ID
b fold change
c gene ontology [28]
and irreversibly suppressed both the osteoblast phenotype
and the osteoblast-speciﬁc gene expression [8]. The expres-
sion of PPARγ2 in marrow MSC increases with aging [14].
Moreover, bone marrow derived from old animals produces
unknown PPARγ activator(s) that stimulates adipocyte dif-
ferentiation and suppresses osteoblast diﬀerentiation [14].
These changes cause alterations in the milieu of intrinsic and
extrinsic signals that determine MSC lineage allocation. For
instance,thiscontributestothepreferentialMSCdiﬀerentia-
tion toward adipocytes and decreased diﬀerentiation toward
osteoblasts that leads to the development of senile osteope-
nia.
PPARγ plays an important role in the maintenance of
bone homeostasis as demonstrated in several animal mod-
els of either bone accrual or bone loss depending on the sta-
tus of PPARγ activity [12, 15–19]. A decrease in PPARγ ac-
tivity resulted in increased bone mass due to increased os-
teoblast number [12, 18], whereas increased PPARγ activityK. R. Shockley et al. 5
Table 2: Genes regulated similarly in PR versus P and P versus V.
Gene symbol Probe ID FC
Gene description Biological process
PR versus P Pv e r s u sV
Akp2 1423611 at −11.5 −2.0 Alkaline phosphatase Marker of osteoblasts
Cd2bp2 1417224 a at −1.9 −1.5 CD2 antigen binding
protein 2 T cell activation
Cd29 (Itgb1) 1426918 at −2.1 −1.5 Integrin beta 1 (ﬁbronectin
receptor beta)
Regulation of progression
through cell cycle, G1/S
transition of mitotic cell
cycle, cell adhesion,
cell-matrix adhesion,
integrin-mediated
signaling pathway,
development, positive
regulation of cell
proliferation, negative
regulation of cell
diﬀerentiation
Cd44 1423760 at −3.9 −5.6 CD44 antigen
Cell surface glycoprotein,
cell adhesion, stem cells,
implicated in tumor
growth and dissemination
Cd105 (Eng) 1432176 a at −2.3 −2.0 Endoglin
Angiogenesis, cell
adhesion, heart
development, regulation of
transforming growth factor
beta receptor signaling
pathway
Cd109 1425658 at −2.8 −5.2 CD109 antigen
Membrane glycoprotein,
elevated expression in
variety of cancers
H2-D1 1451934 at −3.2 −3.0 Histocompatibility 2, D
region locus 1
Immune response,
detected on surface of MSC
and adipocyte stem cells at
low levels and reduced with
passage
H2-K1 1427746 x at −1.6 −1.5 Histocompatibility 2, K1, K
region
Immune response, antigen
presentation
Mki67 1426817 at −4.3 −5.9 Antigen identiﬁed by
monoclonal antibody Ki 67 Meiosis, cell proliferation
Pcna 1417947 at −2.4 −1.7 Proliferating cell nuclear
antigen DNA replication
S100b 1434342 at −4.2 −2.7 S100 protein, beta
polypeptide, neural
Marker of diﬀerentiated
neural cells
Spred1 1460116 s at −1.9 −2.1
Sprouty protein with
EVH-1 domain 1, related
sequence
Inhibition of MAP kinases,
activated in hematopoietic
cells, involved in
mesoderm organization,
inhibit Ras pathway (G
protein)
Spred2 1434403 at −2.3 −1.7
Sprouty protein with
EVH-1 domain 2, related
sequence
As above
Stag1 1434189 at −1.5 −1.7 Stromal antigen 1
Key mediator of
p53-dependent apoptotic
pathway, cell cycle,
chromosome segregation,
mitosis, and cell division
Stag2 1421849 at −1.6 −1.6 Stromal antigen 2 As above6 PPAR Research
Table 2: Continued.
Gene symbol Probe IDa FCb
Gene description Biological processc
PR versus P Pv e r s u sV
Cd1d1 1449130 at 4.9 5.1 CD1d1 antigen
MHC class I-like
glycoprotein, development
and function of natural
killer T lymphocytes
Cd151 1451232 at 1.9 1.5 CD151 antigen
PPARγ positively regulates
it in squamous cell
carcinoma, implicated in
tumor invasiveness
Fabp4 1424155 at 69.6 1.7 Fatty acid binding protein 4 Marker of diﬀerentiated
adipocytes
a Aﬀymetrix probe ID
b fold change
c gene ontology [28]
due to TZD administration led to the bone loss [15–17, 19].
TZD-induced bone loss was accompanied with changes in
the cellular composition of the bone marrow, such as de-
creased numbers of osteoblasts and increased numbers of
adipocytes,andchangesintheMSCphenotypecharacterized
by a loss of MSC plasticity. These changes are characteristics
for aging bone marrow [20]. Recently, several human studies
havedemonstratedthatTZDuseisassociatedwithdecreased
bone mineral density and an increased risk of fractures in
postmenopausal diabetic women [21–23]. This prompted
USFood andDrugAdministration toissueawarningofpos-
sible adverse eﬀects of TZD on human bone.
The development of high throughput analysis of gene ex-
pression using microarrays has advanced studies on genes
and signaling pathways controlled by a single gene prod-
uct. The transcriptional role of PPARγ in either diﬀerenti-
ated cells or functional tissues has been studied using DNA
microarrays, mostly to determine its role in the physiology
during disease and as a result of therapeutic treatment with
TZDs of these target tissues [24–26]. None of these studies,
however, were designed to test for the eﬀect of the PPARγ2
isoform on the molecular signature of MSC. Using a model
of marrow MSC diﬀerentiation under the control of the
PPARγ2 transcription factor, we found that both the pres-
ence of PPARγ2 and its activation with the antidiabetic TZD,
rosiglitazone, resulted in gene expression changes for multi-
ple genes that characterize the stem cell phenotype and their
phenotypic lineages. Even though our model was originally
developed to study the mechanisms by which PPARγ2s u p -
pressed osteoblastogenesis and promoted adipogenesis, our
studies suggest that PPARγ2h a sap r o f o u n de ﬀect on the ex-
pression of signature genes for cell “stemness.”
2. MATERIAL AND METHODS
2.1. CellculturesandRNAisolation
Murine marrow-derived U-33 (previously referred to as
UAMS-33)cellsrepresentaclonalcelllinespontaneouslyim-
mortalizedinthelongtermbonemarrowcultureconditions.
To study the eﬀect of PPARγ2 on marrow mesenchymal
stem cell diﬀerentiation, U-33 cells were stably transfected
with either PPARγ2 expression construct (referred to as U-
33/γ2 cells) or an empty vector control (referred to as U-33/c
cells) as described previously [8]. Several independent clones
were retrieved after transfection and carefully analyzed for
their phenotype. Clone 28.6, representing U-33/γ2 cells, and
clone γc2, representing U-33/c cells, were used in the experi-
mentspresentedinthismanuscript.Cellsweremaintainedin
αMEM supplemented with 10% FBS heat-inactivated (Hy-
clone, Logan, UT), 0.5mg/ml G418 for positive selection
of transfected cells, 100U/ml penicillin, 100μg/ml strepto-
mycin,and0.25μg/mlamphotericin(sigma)at37◦Cinahu-
midiﬁed atmosphere containing 5% CO2. Media and addi-
tives were purchased from Life Technologies (Gaithersburg,
MD).
Cells were propagated for one passage and than seeded
at the density of 3 × 105 cells/cm2. After 48 hours of growth,
when cultures achieved approximately 80% conﬂuency, cells
were treated with either 1μM rosiglitazone or the same vol-
ume of vehicle (DMSO) for 2, 24, and 72 hours, followed
by RNA isolation using RNeasy kit (QIAGEN Inc., Valen-
cia, CA). The replicate experiment was performed indepen-
dently on a fresh batch of cells. Two replicates were used for
microarray analysis. The factorial design of experiment was
2×3×2whichcorrespondedtotwocelllines(withandwith-
out PPARγ2), three time points (2, 24, 72 hours), and two
treatment regiments (rosiglitazone and vehicle).
2.2. Microarrayexperiments
RNA quality was assessed using the Agilent Model 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA). Five
micrograms of total RNA were processed for use on the mi-
croarray by using the Aﬀymetrix GeneChip one-cycle tar-
get labeling kit (Aﬀymetrix, Inc., Santa Clara, CA) accord-
ing to the manufacturer’s recommended protocols. The re-
sultant biotinylated cRNA was fragmented then hybridized
to the GeneChip Mouse Genome 430 2.0 Array (45,000
probe sets used to analyze over 39,000 mouse transcripts
and variants from over 34,000 well-characterized mouse
genes; Aﬀymetrix, Inc.). The arrays were washed, stained,K. R. Shockley et al. 7
Table 3: Genes regulated diﬀerently in PR versus P and P versus V conditions.
Gene symbol Probe IDa FCb
Gene description Biological processc
PR versus P Pv e r s u sV
Actc1 1415927 at −1.5 2.0 Actin, alpha, cardiac
Cytoskeleton organization and
biogenesis, muscle
development, regulation of
heart and muscle contraction
Actg2 1422340 a at −4.7 2.3 Actin, gamma 2, smooth
muscle, enteric
Cytoskeleton organization and
biogenesis, muscle development
Cd97 1418394 a at 2.3 −2.1 CD97 antigen
Cell adhesion, signal
transduction, G-protein
coupled receptor protein
signaling pathway,
neuropeptide signaling pathway
Cd166 (ALCAM) 1437466 at 2.1 −1.5 Activated leukocyte cell
adhesion molecule
Cell adhesion, axon guidance,
motor axon guidance
Cxcl1 1419209 at −2.7 1.8 Chemokine (C-X-C motif)
ligand 1
Regulation of progression
through cell cycle,
inﬂammatory response,
immune response
Cxcl4 1448995 at −2.1 2.8 Chemokine (C-X-C motif)
ligand 4
Chemotaxis, immune response,
negative regulation of
angiogenesis, cytokine, and
chemokine mediated signaling
pathway, platelet activation,
negative regulation of
megakaryocyte diﬀerentiation
Cxcl12 (SDF-1) 1417574 at −2.4 7.5
Chemokine (C-X-C motif)
ligand 12 (stem cell
diﬀerentiation factor)
Patterning of blood vessels,
ameboidal cell migration,
chemotaxis, immune response,
germ cell development and
migration, brain development,
motor axon guidance, T cell
proliferation, induction of
positive chemotaxis
Cxcl16 1456428 at −1.7 1.7 Chemokine (C-X-C motif)
ligand 15
Chemotaxis, inﬂammatory
response, immune response,
signal transduction,
hematopoiesis, neutrophil
chemotaxis
Foxa1 1418496 at −1.5 1.9 Forkhead box A1
Regulation of transcription,
lung development, epithelial
cell diﬀerentiation, branching
morphogenesis of a tube
Kitl 1415854 at −4.1 5.2 Kit ligand
Cell adhesion, germ cell
development, positive
regulation of peptidyl-tyrosine
phosphorylation, cytokine
product associated with
MSC/stromal cells, stem cell
factor
Ntf3 1450803 at −1.5 1.9 Neurotrophin 3
Neuromuscular synaptic
transmission, glial cell fate
determination, axon guidance,
brain and peripheral nervous
system development, epidermis
development, mechanoreceptor
diﬀerentiation, regulation of
neuron apoptosis8 PPAR Research
Table 3: Continued.
Gene symbol Probe IDa FCb
Gene description Biological processc
PR versus P Pv e r s u sV
Pdgfα 1421916 at −2.1 1.6 P l a t e l e td e r i v e dg r o w t hf a c t o r
receptor, alpha polypeptide
Protein amino acid
phosphorylation,
transmembrane receptor protein
tyrosine kinase signaling
pathway, morphogenesis, organ
morphogenesis, extracellular
matrix organization and
biogenesis, male genitalia
development, odontogenesis
Tnfsf11
(RANKL)
1419083 at −1.6 9.2 T u m o rn e c r o s i sf a c t o r( l i g a n d )
superfamily, member 11
Positive regulation of osteoclast
diﬀerentiation and bone
resorption, immune response,
lymph node development
Snai2 1418673 at −6.4 1.9 Snail homolog 2 (Drosophila)
Development of human
melanocytes, regulation of
transcription, DNA dependent,
development, response to
radiation, regulation of survival
gene product activity
Vegfc 1419417 at −5.6 11.5 Vascular endothelial growth
factor C
Regulation of progression
through cell cycle, angiogenesis,
positive regulation of neuroblast
proliferation, development,
positive regulation of cell
proliferation, organ
morphogenesis
a Aﬀymetrix probe ID
b fold change
c gene ontology [28]
and scanned using the Aﬀymetrix Model 450 Fluidics Sta-
tion and Aﬀymetrix Model 3000 scanner using the manu-
facturer’s recommended protocols by the University of Iowa
DNA Core Facility. Raw gene expression measurements were
generated using the microarray suite (MAS) version 5.0 soft-
ware (Aﬀymetrix, Inc.). Statistical assessment of diﬀerential
gene expression is described in Lecka-Czernik et al. [27].
3. RESULTS AND DISCUSSION
An essential role of PPARγ2 in the regulation of marrow
MSC lineage allocation, together with the evidence of its in-
creased activity in MSC with aging [14], prompted us to
studytheeﬀectofPPARγ2ontheexpressionofstemcellgene
markers. Two aspects were examined: the eﬀect of the pres-
ence of PPARγ2 in U-33 stem cells and the eﬀect of PPARγ2
activation with rosiglitazone on stem cell phenotype.
Here we used a model of marrow MSC diﬀerentiation
under the exclusive control of a single protein, PPARγ2.
This system allows for relatively unambiguous studies of the
unique eﬀects of PPARγ2 isoform on MSC phenotype. The
modelofPPARγ2-dependentMSCdiﬀerentiationconsistsof
two cell lines derived from the same parental cell line (U-
33 cells), which either express the PPARγ2 protein (U-33/γ2
cells) or do not express the PPARγ2 protein (U-33/c cells)
[8, 29]. To assess the eﬀects of the presence of PPARγ2o n
the phenotype of U-33 cells in nontreated conditions, we
comparedgeneexpressioninU-33/γ2andU-33/ccellsmain-
tained in basalgrowthconditions (this is referredtoasthe “P
versus V” analysis). This comparison provides information
about PPARγ2 activities, which are either ligand indepen-
dent or acquired as a result of activation with natural ligands
present in the growth media or endogenously produced by
tested cells. The results of “P versus V” analysis may provide
information on a role of PPARγ2 in a continuum of changes
that occur in stem cells during aging. To assess an eﬀect of
rosiglitazone on the expression of stem cell-related genes,
we compared gene expression in U-33/γ2 cells treated with
rosiglitazone and nontreated U-33/γ2 cells (this is referred to
as the “PR versus P” analysis). This analysis provides impor-
tant information on the eﬀects of rosiglitazone on the stem
cell phenotype. Finally, comparison of the results of both an-
alyzes provides information on diﬀerences between endoge-
nous and artiﬁcially induced PPARγ2 activities in respect to
stem cell gene expression.
To avoid diﬀerencesinthecellphenotypeduetodiﬀerent
rates of cell growth, we chose the 72-hour time point for the
analysis of gene expression (see Section 2). In basal growth
conditions at this time point, cell cultures of U-33/γ2a n d
U-33/c were in state of conﬂuence, cells acquired ﬁbroblast-
like appearance and cell cultures were indistinguishable
morphologically from each other. In contrast, U-33/γ2c e l l sK. R. Shockley et al. 9
Table 4: Genes whose expression was not aﬀected in P versus V and PR versus P conditions.
Gene symbol Probe IDa Gene description
Afp 1416645 a at Alpha fetoprotein
Cd34 1416072 at CD34 antigen
Cd3z 1438392 at CD3 antigen, zeta polypeptide
Cd5l 1449193 at CD5 antigen like
Cd6 1451910 a at CD6 antigen
Cd8b1 1448569 at CD8 antigen, beta chain 1
Cd22 1419769 at CD22 antigen
Cd53 1439589 at CD53 antigen
Cd86 1420404 at CD86 antigen
Cd164 1431527 at CD164 antigen
Cd209e 1420582 at Cd209e antigen
Cdh15 1418602 at Protocadherin 15
Cer1 1450257 at Cerberus 1 homolog
Col6a2 1452250 a at Procollagen, type VI, alpha 2
Erbb2ip 1439080 at Erbb2 interacting protein
Erbb3 1452482 at V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
Fabp7 1450779 at Fatty acid binding protein 7, brain
Fzd9 1427529 at Frizzled homolog 9
Gata2 1450333 a at GATA binding protein 2
Gcg 1425952 a at Glucagon
Gcm2 1420455 at Glial cells missing homolog 2
Gfap 1440142 s at Glial ﬁbrillary acidic protein
Gjb3 1416715 at Gap junction membrane channel protein beta 3
Gjb4 1422179 at Gap junction membrane channel protein beta 4
Ina 1418178 at Internexin neuronal intermediate ﬁlament protein, alpha
Ins1 1422447 at Insulin I
Isl1 1444129 at ISL1 transcription factor, LIM/homeodomain (islet 1)
Krt1-14 1460347 at Keratin complex 1, acidic, gene 14
Krt1-17 1423227 at Keratin complex 1, acidic, gene 17
Krt2-8 1435989 x at Keratin complex 2, basic, gene 8
Mbp 1454651 x at Myelin basic protein
Mtap1b 1450397 at Microtubule-associated protein 1 B
Myh11 1448962 at Myosin, heavy polypeptide 11, smooth muscle
Ncam1 1439556 at Neural cell adhesion molecule 1
Ncam2 1425301 at Neural cell adhesion molecule 2
Nes 1453997 a at Nestin
Ngfr 1421241 at Nerve growth factor receptor (TNFR superfamily, member 16)
Nkx2-2 1421112 at NK2 transcription factor related, locus 2 (Drosophila)
Numb 1425368 a at Numb gene homolog (Drosophila)
Olig1 1416149 at Oligodendrocyte transcription factor 1
Pax6 1456342 at Paired box gene 6
Pou3f3 1422331 at POU domain, class 3, transcription factor 3
Pou6f1 1420749 a at POU domain, class 6, transcription factor 1
Prox1 1457432 at Prospero-related homeobox 1
Ptprc 1440165 at Protein tyrosine phosphatase, receptor type, C
Slc1a2 1451627 a at Solute carrier family 1 (glial high aﬃnity glutamate transporter), member 2
Slc1a6 1418933 at Solute carrier family 1 (high aﬃnity aspartate/glutamate transporter), member 6
Sox1 1422205 at SRY-box containing gene 1
Sox2 1416967 at SRY-box containing gene 2
Syn1 1453467 s at Synapsin I
Tubb3 1415978 at Tubulin, beta 3
Zfp110 1450998 at Zinc ﬁnger protein 110
a Aﬀymetrix probe ID10 PPAR Research
treated for 72 hours with rosiglitazone acquired adipocyte
phenotype typiﬁed by large fat droplets. A morphological
appearance of U-33/c cells treated with rosiglitazone was in-
distinguishable from nontreated U-33/c cells as well as non-
treated U-33/γ2 cells.
There are no known exclusive markers for MSC. How-
ever, based on extensive work with MSCs and other stem
cell populations, several proteins have emerged as candidate
markersassociatedwith astemcellphenotype. Theseentities
include ATP-binding cassette g2 (Abcg2), cell surface antigen
CD44, stem cell factor or kit ligand (SCF/Kitl), epidermal
growth factor receptor (Egfr), early growth response factor 2
(Egr2), leukemia inhibitory factor (Lif), leukemia inhibitory
factor receptor (Lifr), and stromal-derived factor/CXC-
chemokine ligand 12 (SDF-1/CXCL12). Based on the avail-
able published information for stem cell gene expression
for the analysis, we arbitrarily chose 135 genes that repre-
sent markers of either early or lineage committed stem cells
[9,30–34].Theanalysisshowedthattheexpressionof38%of
analyzedgeneswasnotaﬀectedbyactivationstateofPPARγ2
(see Table 4), the expression of 28% genes was exclusively
aﬀected by the presence of PPARγ2 (“P versus V” analysis)
(see Table 1(a)), and the expression of 10% genes was exclu-
sively aﬀected by rosiglitazone-activated PPARγ2( “ P Rv e r -
sus P” analysis) (see Table 1(b)). The genes whose expres-
sion was aﬀected by both rosiglitazone-activated and non-
activated PPARγ2 constituted 24% of the total genes studied;
their expression was aﬀected in equal proportion either sim-
ilarly (see Table 2) or in the opposite direction in these two
conditions (see Table 3).
Comparison of the two cell lines indicates that a major-
ity of analyzed genes are up-regulated in U-33/γ2v e r s u sU -
33/c cells (see Tables 1(a) and 3). Most of these genes are
characteristic for stem cells of hematopoietic and neural lin-
eages while some of them are expected to be up regulated
in hematopoiesis supporting stromal cells (e.g. Kitl, RANKL
(Table 1(a)), and the CXCL family (Tables 1(a) and 3)).
These interesting observations have at least two reason-
ableinterpretations.Theﬁrstinterpretationsuggeststhatob-
served diﬀerences are a reﬂection of diﬀerent phenotypes
of the two individual parental cells from which each of
the two clones originated. Hence, diﬀerences in gene ex-
pression between both cell lines are PPARγ2-independent.
The second possibility suggests that these diﬀerences are
PPARγ2-dependent and result from either PPARγ2 ligand-
independent activity or activity acquired from endogenous
ligand. Several lines of evidence suggest a correlation be-
tween the adipocyte-like phenotype of marrow stroma cells
and support for hematopoiesis [35, 36]. Hematopoiesis de-
pends heavily on the microenvironment provided by mes-
enchymal cell compartment in the marrow and the ability
of these cells to produce growth factors and cytokines that
act in a paracrine fashion to inﬂuence the diﬀerentiation
of hematopoietic progenitors. In the long term bone mar-
row cultures, an in vitro system of hematopoietic cell dif-
ferentiation, stroma cell support for myelopoiesis, is pro-
vided by cultures consisting mostly of adipocytes [35, 37].
Similarly, in vivo studies in a model of SAMP6 mice that
are characterized by senile osteopenia due to a diminished
number of osteoblasts and increased myelopoiesis, correlates
positively with an increased number of marrow adipocytes
[38]. Interestingly, U-33/γ2 cells support osteoclastogenesis
much better than U-33/c cells (unpublished observation),
in part due to relatively higher RANKL (9-fold in “P ver-
sus V,” Table 3) and lower OPG (−34.6-fold in “P versus
V”; Table 1(a)) expression. Another important regulator of
bone marrow hematopoiesis, including osteoclastogenesis, is
represented by the chemokine CXCL12 or SDF-1 [39, 40].
Growing experimental evidence indicates that CXCL12 and
its receptor CXCR4 axis is not only required for hematopoi-
etic stem cell signaling but also has a crucial role in the for-
mation of multiple organ systems during embryogenesis as
well as adult nonhematopoietic tissue regeneration and tu-
morigenesis [39]. According to our analysis, an expression of
CXCL12,butnotCXCR4,isupregulatedinU-33/γ2cells(“P
versus V”) and suppressed by PPARγ2-activated with rosigli-
tazone (“PR versus P”) (see Table 3). Thus, it is conceiv-
able that mesenchymal cells which express PPARγ2a c q u i r e
the adipocyte-like phenotype typiﬁed by the production of
number of cytokines and support hematopoietic stem cell
diﬀerentiation.
While PPARγ2h a sap o s i t i v ee ﬀect on the stromal phe-
notype supporting hematopoiesis, it has a negative eﬀect on
the expression of “stemness” genes. The expression of LIF
cytokine and its receptor, a regulatory system required for
the stem cell self renewal, is signiﬁcantly suppressed in U-
33/γ2 cells as compared to U-33/c cells (see Table 1(a)). In-
terestingly, activation of PPARγ2 with rosiglitazone did not
aﬀect the expression of these genes. The presence of PPARγ2
in U-33/γ2 cells suppresses the expression of Egr2/Krox20, a
stem cell-speciﬁc transcription factor with a role in the de-
velopment of nervous system and endochondrial bone for-
mation [41]. Egr2/Krox20 also regulates osteoblast diﬀeren-
tiation and osteocalcin expression [42]. Again, rosiglitazone
does not aﬀect Egr2/Krox20 gene expression (see Table 1(a)).
PPARγ2 cellular presence also aﬀects expression of Zfp42
transcription factor,whichis a markerof humanand murine
embryonic stem (ES) cells. Expression of Zfp42 is down reg-
ulatedduringEScelldiﬀerentiation[43].Anartiﬁcialknock-
down of Zfp42 with RNAi resulted in spontaneous diﬀeren-
tiation of ES cells toward endoderm and mesoderm lineages,
whereas its overexpression led to the loss of self-renewal ca-
pacity of ES cells [44].
The expression of ABCG2, a well recognized stem cell
marker [45], was down-regulated in “PR versus P” (−3.1
fold) (see Table 1(b)) and slightly in “P versus V” (−1.3
fold, P<. 01) conditions (not shown). ABCG2 represents
an ATP-binding cassette (ABC) transporter which serves to
eﬄux certain xenobiotics (including anticancer drugs) that
can lead to the development of multidrug resistance syn-
drome. This is a signiﬁcant obstacle in cancer treatment
[46]. This gene is also considered to be a marker of primi-
tive pluripotent stem cells, termed “side population,” which
were identiﬁed based on their ability to exclude Hoest dye
[45]. The ability to exclude a variety of substances may com-
prise a mechanism that protects stem cells from exogeneous
and endogeneous toxins. Finding that ABCG2 expression is
down regulated by PPARγ2, especially after activation withK. R. Shockley et al. 11
rosiglitazone, implicates PPARγ2 as a negative regulator of
stem cell phenotype as well as a negative regulator of mul-
tidrug resistance. Similarly, Egfr a marker of early stem cells
is down regulated by PPARγ2 when activated with rosiglita-
zone [47].
Interestingly, however, the expressions of Oct-4
(POU5f1) and FGF4, well recognized embryonic stem
cell markers highly expressed in the totipotent and pluripo-
tent ES cells [48, 49] are up regulated in U-33/γ2c e l l s
compared to U-33/c cells and are not aﬀected in U-33/γ2
cells treated with rosiglitazone (see Table 1(a)).
Another interesting grouping consists of genes whose ex-
pressionisdiﬀerentiallyregulatedbybothactivatedandnon-
activated PPARγ2 (see Table 2). A number of genes impli-
catedinearlystemcellmaintenanceandrecruitment,among
themCD44, H2-D1, PCNA, CD109, Spred1 and 2, and Stag1
and 2, are down regulated in U-33/γ2 cells in both basal con-
ditions and upon rosiglitazone treatment.
The last category represents gene markers speciﬁc for
terminally-diﬀerentiated cells.Consistent with the proad-
ipocytic and antiosteoblastic activities of PPARγ2a c t i v a t e d
with rosiglitazone, the expression of the gene encoding
FABP4 increases, whereas an expression of the gene underly-
ing alkaline phosphatase decreases. Markers of the neuronal
phenotype are either decreased (S100b, Table 2)o rn o ta f -
fected (nestin and NCAMs, Table 4), and the expression of
CD34, a bona ﬁde marker for cells of hematopoietic lin-
eage, is not aﬀected (see Table 4). However, the expression
patterns of gene markers characteristic for embryonic stem
cells and a large number of markers that are associated with
a nonmesenchymal phenotype, including markers of diﬀer-
ent hematopoietic and neuronal lineages, indicates that mar-
rowmesenchymalU-33cellspossessamixedphenotypewith
some characteristics of early primitive pluripotent stem cells
and lineage oriented mesenchymal cells.
In conclusion, PPARγ2 is a powerful modulator of the
stem cell phenotype and its activation with antidiabetic
TZDs aﬀect the expression of “stemness” genes. It is unclear
atthistimewhether,andtowhatextent,PPARy2isexpressed
in stem cells in vivo and whether this key transcription fac-
tor plays a signiﬁcant role in stem cell biology. However, the
ﬁndings presented here, together with previously published
evidence of increased PPARγ2 expression in MSCs with ag-
ing [14] and a loss of marrow MSC plasticity or ability to
convert between phenotypes as a result of aging and TZD
therapy [20], suggest that aging and TZD therapy may aﬀect
stem cell phenotype through modulation of PPARγ2a c t i v -
ity. These observations may also have important therapeutic
consequences and indicate a need for more detailed studies
of PPARγ2r o l ei ns t e mc e l lb i o l o g y .
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